1 |
Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Front Immunol 2022;13:882064. [DOI: 10.3389/fimmu.2022.882064] [Reference Citation Analysis]
|
2 |
Xue J, Cheng J, Ma X, Shi Y, Yin H, Gao Y, Li J. Role of Ras-related Nuclear Protein/Polypyrimidine Tract Binding Protein in Facilitating the Replication of Hepatitis C Virus. J Clin Transl Hepatol 2021;9:458-65. [PMID: 34447674 DOI: 10.14218/JCTH.2020.00122] [Reference Citation Analysis]
|
3 |
Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
|
4 |
Cacciola I, Pitrone C, Franzè MS, Mazzeo C, Muscianisi M, Porcari S, Pintabona G, Morace C, Basile G, Cucinotta E, Pollicino T, Raimondo G. Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. Ann Hepatol 2021;:100578. [PMID: 34752948 DOI: 10.1016/j.aohep.2021.100578] [Reference Citation Analysis]
|